Bowen Hanes & Co. Inc. Acquires 1,785 Shares of Intuitive Surgical, Inc. $ISRG

Bowen Hanes & Co. Inc. boosted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 180,975 shares of the medical equipment provider’s stock after buying an additional 1,785 shares during the period. Intuitive Surgical makes up 2.0% of Bowen Hanes & Co. Inc.’s investment portfolio, making the stock its 13th biggest holding. Bowen Hanes & Co. Inc.’s holdings in Intuitive Surgical were worth $83,428,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ISRG. Bank of Nova Scotia grew its holdings in Intuitive Surgical by 13.9% during the 1st quarter. Bank of Nova Scotia now owns 618,138 shares of the medical equipment provider’s stock valued at $284,959,000 after buying an additional 75,579 shares in the last quarter. Gibbs Wealth Management lifted its holdings in shares of Intuitive Surgical by 58.7% in the first quarter. Gibbs Wealth Management now owns 3,557 shares of the medical equipment provider’s stock worth $1,640,000 after buying an additional 1,316 shares in the last quarter. Alamar Capital Management LLC bought a new position in shares of Intuitive Surgical in the first quarter valued at approximately $1,643,000. Davis R M Inc. boosted its position in shares of Intuitive Surgical by 1.7% in the first quarter. Davis R M Inc. now owns 56,581 shares of the medical equipment provider’s stock valued at $26,083,000 after acquiring an additional 943 shares during the period. Finally, Cetera Investment Advisers grew its stake in Intuitive Surgical by 2.8% during the first quarter. Cetera Investment Advisers now owns 120,628 shares of the medical equipment provider’s stock valued at $55,608,000 after acquiring an additional 3,236 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Down 2.5%

NASDAQ ISRG opened at $332.02 on Friday. The stock’s 50-day simple moving average is $408.55 and its two-hundred day simple moving average is $460.85. Intuitive Surgical, Inc. has a twelve month low of $328.57 and a twelve month high of $603.88. The company has a market capitalization of $117.30 billion, a price-to-earnings ratio of 38.03, a PEG ratio of 2.47 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.48 by $0.32. The firm had revenue of $2.89 billion during the quarter, compared to analysts’ expectations of $2.83 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.The company’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.81 EPS. On average, equities analysts expect that Intuitive Surgical, Inc. will post 8.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Leerink Partners cut their price target on shares of Intuitive Surgical from $573.00 to $454.00 and set an “outperform” rating for the company in a report on Friday, July 17th. Deutsche Bank Aktiengesellschaft lowered their price objective on Intuitive Surgical from $440.00 to $366.00 and set a “sell” rating on the stock in a research report on Tuesday, June 2nd. TD Cowen dropped their price objective on Intuitive Surgical from $585.00 to $520.00 and set a “buy” rating for the company in a research note on Monday, July 13th. Robert W. Baird reduced their target price on Intuitive Surgical from $525.00 to $500.00 and set an “outperform” rating for the company in a research report on Friday, July 17th. Finally, Wall Street Zen upgraded Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Twenty-one investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $523.46.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive outlined its AI-enabled future for surgical care, including a five-layer AI framework and real-time telesurgical collaboration, reinforcing its innovation pipeline and potential to deepen its competitive moat. Intuitive Shares Vision for an AI-Enabled Future of Healthcare
• Positive Sentiment: Analyst coverage continues to view ISRG as an attractive long-term MedTech growth name, citing the expanding robotic surgery ecosystem and innovation pipeline. ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now?
• Positive Sentiment: CONMED expanded AirSeal robotic compatibility for the da Vinci 5 hex cannula, which supports broader adoption of Intuitive’s newest system. CONMED Expands AirSeal Robotic Solution for da Vinci 5 Hex Cannula
• Neutral Sentiment: Multiple analyst roundups reiterated that Wall Street generally still rates ISRG favorably, but these reports were largely commentary rather than new fundamental catalysts. Wall Street Analysts Think Intuitive Surgical (ISRG) Is a Good Investment: Is It?
• Neutral Sentiment: Recent coverage also emphasized that Intuitive remains a premium valuation story, with valuation support coming from margins, AI software, and international growth, but with slower U.S. procedure growth creating uncertainty. Can ISRG Maintain Its Premium Valuation Amid Slower Procedure Growth?
• Negative Sentiment: J&J’s entry into U.S. robotic surgery increased concerns that da Vinci’s dominance could face real competition, helping pressure sentiment toward ISRG. J&J enters US robotic surgery market after device gets marketing authorization
• Negative Sentiment: Analysts have also trimmed fair value estimates and growth assumptions, citing slower procedure growth and broader MedTech multiple compression, which reinforces concerns that upside may be more limited near term. Intuitive Surgical (ISRG) Stock Sees Fair Value Cut As Analysts Trim Growth Views

Insiders Place Their Bets

In other Intuitive Surgical news, Director Amy L. Ladd sold 119 shares of the company’s stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $463.50, for a total value of $55,156.50. Following the completion of the sale, the director owned 120 shares of the company’s stock, valued at $55,620. This represents a 49.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Iman Jeddi sold 5,625 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the transaction, the senior vice president owned 6,463 shares in the company, valued at $2,718,014.65. The trade was a 46.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,169 shares of company stock valued at $3,059,135 over the last quarter. 0.60% of the stock is owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.